GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.
Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).
The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback